Garbe, C. et al. (2011) Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist, 16, 5-24.
Hamid, O. et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med., 369, 134-144.
Ribas, A. et al. (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA, 315, 1600-1609.
Sloan, E.K. et al. (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res., 70, 7042-7052.
Nilsson, M.B., et al. (2017) Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with beta-blockers. Sci Transl Med, 9, 415.
Kroenke, C.H. et al. (2006) Social networks, social support, and survival after breast cancer diagnosis. J. Clin. Oncol., 24, 1105-1111.
Sprehn, G.C. et al. (2009) Decreased cancer survival in individuals separated at time of diagnosis: Critical period for cancer pathophysiology Cancer, 115, 5108-5116.
Spiegel, D. et al. (2001) Psychoneuroimmune and endocrine pathways in cancer: Effects of stress and support. Semin. Clin. Neuropsychiatry, 6, 252-265.
Kanno, J. et al. (1997) Effect of restraint stress on immune system and experimental B16 melanoma metastasis in aged mice. Mech. Ageing Dev., 93, 107-117.
Sommershof, A. et al. (2017) Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma. Brain. Behav. Immun., 65, 140-149.
Neumann, I.D. et al. (2012) Balance of brain oxytocin and vasopressin: Implications for anxiety, depression, and social behaviors. Trends Neurosci., 35, 649-659.
Sippel, L.M., et al. (2017) Oxytocin and stress-related disorders: Neurobiological mechanisms and treatment opportunities. Chronic Stress (Thousand Oaks), 1.
Jezova, D. et al. (1995) Vasopressin and oxytocin in stress. Ann. N. Y. Acad. Sci., 771, 192-203.
Danevova, V. et al. (2013) Kinetics of oxytocin response to repeated restraint stress and/or chronic cold exposure. Horm. Metab. Res., 45, 845-848.
Cassoni, P. et al. (2004) Oxytocin and oxytocin receptors in cancer cells and proliferation. J. Neuroendocrinol., 16, 362-364.
Roehrborn, C.G. et al. (2001) Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology, 57, 1087-1092.
Jeong, J.Y. et al. (2013) Effects of chronic restraint stress on body weight, food intake, and hypothalamic gene expressions in mice. Endocrinol. Metab. (Seoul)., 28, 288-296.
Ahn, S. et al. (2003) Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc. Natl. Acad. Sci. USA, 100, 1740-1744.
Folkman, J. (1971) Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
Sá-Rocha, V.M. et al. (2006) Variations in behavior, innate immunity and host resistance to B16F10 melanoma growth in mice that present social stable hierarchical ranks. Physiol. Behav., 88, 108-115.
Luttrell, L.M. et al. (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science, 283, 655-661.
Tohgo, A. et al. (2002) beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J. Biol. Chem., 277, 9429-9436.
Tohgo, A. et al. (2003) The stability of the G protein-coupled receptorbeta- A rrestin interaction determines the mechanism and functional consequence of ERK activation. J. Biol. Chem., 278, 6258-6267.
Luttrell, L.M. et al. (2001) Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc. Natl. Acad. Sci. USA, 98, 2449-2454.
McDonald, P.H. et al. (2000) Beta-arrestin 2: A receptor-regulated MAPK scaffold for the activation of JNK3. Science, 290, 1574-1577.
Knobloch, H.S. et al. (2012) Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron, 73, 553-566.
Engert, V. et al. (2016) Boosting recovery rather than buffering reactivity: Higher stress-induced oxytocin secretion is associated with increased cortisol reactivity and faster vagal recovery after acute psychosocial stress. Psychoneuroendocrinology, 74, 111-120.
Jong, T.R. et al. (2015) Salivary oxytocin concentrations in response to running, sexual self-stimulation, breastfeeding and the TSST: The Regensburg Oxytocin Challenge (ROC) study. Psychoneuroendocrinology, 62, 381-388.
Cattaneo, M.G. et al. (2008) Oxytocin stimulates migration and invasion in human endothelial cells. Br. J. Pharmacol., 153, 728-736.
Gimpl, G. et al. (2008) Oxytocin receptors: Ligand binding, signalling and cholesterol dependence. Prog. Brain Res., 170, 193-204.
Cassoni, P. et al. (1994) Oxytocin inhibits proliferation of human breast cancer cell lines. Virchows Arch., 425, 467-472.
Bussolati, G. et al. (1995) Effect of oxytocin on breast carcinoma cell growth. Adv. Exp. Med. Biol., 395, 553-554.
Cassoni, P. et al. (2000) Oxytocin receptors in human adenocarcinomas of the endometrium: Presence and biological significance. J. Pathol., 190, 470-477.
Reversi, A. et al. (2005) Oxytocin receptor signaling in myoepithelial and cancer cells. J. Mammary Gland Biol. Neoplasia, 10, 221-229.
Whittington, K. et al. (2007) The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: Implications for benign prostatic hyperplasia and carcinoma of the prostate. Prostate, 67, 1132-1142.
Cassoni, P. et al. (1998) Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. Int. J. Cancer, 77, 695-700.
Petersson, M. (2008) Opposite effects of oxytocin on proliferation of osteosarcoma cell lines. Regul. Pept., 150, 50-54.
Cassoni, P. et al. (2001) Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. Endocrinology, 142, 1130-1136.
Péqueux, C. et al. (2004) Oxytocin- A nd vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr. Relat. Cancer, 11, 871-885.
Morita, T. et al. (2004) Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. Int. J. Cancer, 109, 525-532.
Copland, J.A. et al. (1999) Demonstration of functional oxytocin receptors in human breast Hs578T cells and their up-regulation through a protein kinase C-dependent pathway. Endocrinology, 140, 2258-2267.
Guzzi, F. et al. (2002) Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene, 21, 1658-1667.
Oakley, R.H. et al. (2001) Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-betaarrestin complexes after receptor endocytosis. J. Biol. Chem., 276, 19452-19460.
Drake, M.T. et al. (2008) beta-arrestin-biased agonism at the beta2- A drenergic receptor. J. Biol. Chem., 283, 5669-5676.
Gesty-Palmer, D. et al. (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Transl. Med., 1, 1ra1.
Lefkowitz, R.J. et al. (2005) Transduction of receptor signals by betaarrestins. Science, 308, 512-517.
Noma, T. et al. (2007) Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest., 117, 2445-2458.
Shenoy, S.K. et al. (2006) beta-arrestin-dependent, G proteinindependent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem., 281, 1261-1273.
Wei, H. et al. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. USA, 100, 10782-10787.
Gesty-Palmer, D. et al. (2006) Distinct beta-arrestin- A nd G proteindependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem., 281, 10856-10864.
Charest, P.G. et al. (2007) The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell. Signal., 19, 32-41.
Grotegut, C.A. et al. (2011) -Arrestin mediates oxytocin receptor signaling, which regulates uterine contractility and cellular migration. Am. J. Physiol. Endocrinol. Metab., 300, E468-E477.
Kovacs, J.J. et al. (2009) Arrestin development: Emerging roles for betaarrestins in developmental signaling pathways. Dev. Cell, 17, 443-458.
